ABSTRACT Background Skin aging arises from intrinsic factors and is accelerated by extrinsic factors such as ultraviolet exposure and pollution, leading to inflammation, barrier impairment, and pigmentary changes. Energy‐based devices and chemical peels are widely used for facial rejuvenation, but post‐procedural recovery remains challenging due to barrier disruption and risk of dyschromia. Aims This review evaluates the clinical evidence for Macrocystis pyrifera ferment (MPF)‐containing serum as an adjunctive skincare approach to support pre‐ and post‐procedure recovery, focusing on anti‐inflammatory effects, barrier repair, and pigmentary improvement. Methods A panel of eight expert dermatologists reviewed clinical data on MPF and MPF‐containing serum, focusing on its potential applications in cosmetic dermatology. This manuscript presents the clinical evidence alongside insights from the panel discussion. Results In a clinical erythema model, pretreatment with MPF significantly reduced erythema and accelerated recovery from irritation. Twice‐daily application of MPF‐containing serum improved hydration and reduced transepidermal water loss (TEWL), with moisturization increasing by 14% at Week 4 and 16% at Week 8, and TEWL decreasing by 11% at Week 8. Tape‐stripping studies confirmed a 30% improvement in barrier resilience at Week 8. In a trial of 52 women (ages 20–62, Fitzpatrick I–VI), twice‐daily application of MPF‐containing serum progressively improved post‐inflammatory erythema and hyperpigmentation, achieving nearly a 50% reduction in spot intensity and contrast by Week 12. Benefits were measurable as early as Week 2, and all participants demonstrated improvement by study end. Conclusions MPF‐containing serum demonstrates anti‐inflammatory, barrier‐strengthening, and dyschromia‐improving properties, making it a safe and effective adjunct to dermatologic procedures. While current findings support its utility in post‐procedural care, further large‐scale, diverse clinical trials are warranted.
Background Glabellar neuromodulator injections are frequently guided by skin surface contraction patterns, assuming that visible rhytids reflect underlying muscular anatomy. However, emerging anatomical and imaging evidence has questioned the clinical relevance of pattern-based treatment adaptations. Objective To prospectively evaluate whether different glabellar contraction patterns influence clinical and patient-reported outcomes when a standardized, anatomy-based, FDA-approved 5-point injection algorithm is applied. Methods This prospective, multicenter clinical study enrolled 125 patients treated across five independent centers. Patients were classified into five previously described glabellar contraction patterns (V-shape, U-shape, converging arrows, omega, and inverted omega) based on standardized photographs during maximal frowning. All patients received neuromodulator injections following the same standardized 5-point technique using either onabotulinumtoxinA or abobotulinumtoxinA with dose equivalence. Clinical outcomes were assessed using the Glabellar Line Severity Scale (GLSS) at baseline, 15 days, and 90 days, while patient-reported outcomes were evaluated with the Global Aesthetic Improvement Scale (GAIS) at 90 days. Statistical analyses included non-parametric group comparisons and multivariate ordinal logistic regression. Results A total of 119 patients completed the study. A significant improvement in GLSS was observed at 15 days (p < 0.001), followed by partial regression at 90 days (p < 0.001 vs. baseline). No statistically significant differences in GLSS or GAIS were identified between contraction pattern groups at any time point (all p > 0.05). Multivariate analysis demonstrated that age and body mass index significantly influenced treatment outcomes, whereas glabellar contraction patterns and Fitzpatrick skin type did not. Mild, transient local adverse events were observed and resolved spontaneously. Conclusion Glabellar contraction patterns do not significantly affect clinical or patient-reported outcomes when neuromodulator injections are performed using a standardized, anatomy-based 5-point technique. These findings support prioritizing muscular anatomy and patient-specific biological factors over surface rhytid patterns in glabellar neuromodulation.